COVID-19-Induced Actemra Shortage Causes Headaches For CAR-T Centers
Some Hematologists Report Having Problems Scheduling Cell Therapy
While some cancer centers report sufficient stocks of the drug, they have already been turning to potential alternatives due to supply issues that could last for weeks or months.
